Skip to content

Study · Case report or series · n = 1 · 2026

7 results

Liraglutide-Induced Acute Hepatocellular Injury With Positive Rechallenge: A Case Report and Literature Review.

Adi M, Ashraf A, Eshimova S, Husanov S

Clinical medicine insights. Case reports15 Jun 2026

PMID42311917 (opens in a new tab)PMCIDPMC13269733 (opens in a new tab)DOI10.1177/11795476261461221 (opens in a new tab)PepBankPUB-42311917
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 58-year-old woman with obesity and type 2 diabetes, alanine aminotransferase was 876 U/L 12 weeks after liraglutide initiation.

    In plain wordsIn one 58-year-old woman with obesity and type 2 diabetes, ALT was high 12 weeks after liraglutide was started.

    Peptide
    Liraglutide
    Outcome
    IncreaseAlanine aminotransferase
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    ALT
    876 U/L

    Source sentences

    Summary
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.
  2. 02HumanCase report or seriesSafety outcome

    In a 58-year-old woman with obesity and type 2 diabetes, aspartate aminotransferase was 702 U/L 12 weeks after liraglutide initiation.

    In plain wordsIn one 58-year-old woman with obesity and type 2 diabetes, AST was high 12 weeks after liraglutide was started.

    Peptide
    Liraglutide
    Outcome
    IncreaseAspartate aminotransferase
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    AST
    702 U/L

    Source sentences

    Summary
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.
  3. 03HumanCase report or seriesSafety outcome

    In a 58-year-old woman with obesity and type 2 diabetes, liver enzymes improved rapidly after liraglutide cessation.

    In plain wordsIn one 58-year-old woman with obesity and type 2 diabetes, liver enzymes improved rapidly after liraglutide was stopped.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedLiver enzyme levels after discontinuation
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liver enzyme levels improved rapidly following drug discontinuation.
    1 context sentence
    Summary · context
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.
  4. 04HumanCase report or seriesSafety outcome

    On supervised liraglutide rechallenge in a 58-year-old woman with obesity and type 2 diabetes, alanine aminotransferase was 1245 U/L within 10 days.

    In plain wordsIn one woman with obesity and T2D, ALT was high within ten days of supervised liraglutide rechallenge.

    Peptide
    Liraglutide
    Outcome
    IncreaseAlanine aminotransferase on rechallenge
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    ALT
    1245 U/L
    rechallenge

    Source sentences

    Summary
    A supervised rechallenge resulted in recurrence of severe transaminitis (ALT 1245 U/L, AST 980 U/L) within 10 days, with RUCAM score of 11 supporting a highly probable drug-induced liver injury.
    1 context sentence
    Summary · context
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.
  5. 05HumanCase report or seriesSafety outcome

    On supervised liraglutide rechallenge in a 58-year-old woman with obesity and type 2 diabetes, aspartate aminotransferase was 980 U/L within 10 days.

    In plain wordsIn one woman with obesity and T2D, AST was high within ten days of supervised liraglutide rechallenge.

    Peptide
    Liraglutide
    Outcome
    IncreaseAspartate aminotransferase on rechallenge
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    AST
    980 U/L
    rechallenge

    Source sentences

    Summary
    A supervised rechallenge resulted in recurrence of severe transaminitis (ALT 1245 U/L, AST 980 U/L) within 10 days, with RUCAM score of 11 supporting a highly probable drug-induced liver injury.
    1 context sentence
    Summary · context
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.
  6. 06HumanCase report or seriesSafety outcome

    In a 58-year-old woman with obesity and type 2 diabetes, a RUCAM score of 11 supported highly probable liraglutide-induced liver injury.

    In plain wordsIn one woman with obesity and T2D, the causality assessment rated liraglutide-related liver injury highly probable.

    Peptide
    Liraglutide
    Outcome
    Not applicableDrug-induced liver injury causality
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    RUCAM score
    11
    rechallenge

    Source sentences

    Summary
    A supervised rechallenge resulted in recurrence of severe transaminitis (ALT 1245 U/L, AST 980 U/L) within 10 days, with RUCAM score of 11 supporting a highly probable drug-induced liver injury.
    1 context sentence
    Summary · context
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.
  7. 07HumanCase report or seriesSafety outcome

    In a 58-year-old woman with obesity and type 2 diabetes, marked hepatocellular injury occurred 12 weeks after liraglutide initiation.

    In plain wordsIn one woman with obesity and T2D, marked liver injury occurred twelve weeks after liraglutide initiation.

    Peptide
    Liraglutide
    Outcome
    Not applicableHepatocellular injury
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U/L and aspartate aminotransferase (AST) 702 U/L after exclusion of alternative causes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.